Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | BPTF | Q12830 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16722815 | 0.88 | GAA (0.58) | ALDH1A1GAAHSD17B10TSHRKMT2A | |
| SCHEMBL11248938 | 0.80 | ALDH1A1 (0.47) | ALDH1A1BPTFSMN1; SMN2HSD11B1NPSR1 | |
| SCHEMBL13660316 | 0.79 | ALDH1A1 (0.50) | ALDH1A1BPTFSMN1; SMN2HSD11B1TSHR | |
| SCHEMBL12321006 | 0.77 | ALDH1A1 (0.45) | ALDH1A1BPTFSMN1; SMN2HSD11B1NPSR1 | |
| SCHEMBL1072911 | 0.76 | ALDH1A1 (0.61) | ALDH1A1BPTFSMN1; SMN2HSD11B1NPSR1 | |
| SCHEMBL18751696 | 0.75 | KMT2A (0.35) | GAAKMT2A | |
| SCHEMBL3021927 | 0.75 | ALDH1A1 (0.59) | ALDH1A1BPTFSMN1; SMN2HSD11B1NPSR1 | |
| SCHEMBL134689 | 0.75 | ALDH1A1 (0.50) | ALDH1A1BPTFSMN1; SMN2HSD11B1NPSR1 | |
| SCHEMBL3454752 | 0.75 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2NPSR1EPHX2P2RX7 | |
| Adamantaneacetic Acid SCHEMBL24688608 | 0.73 | ALDH1A1 (0.62) | ALDH1A1BPTFSMN1; SMN2HSD11B1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | TNF, NFATC1, IL2 | ALDH1A1 702/4885BPTF 1711/4885SMN1; SMN2 3725/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | ALDH1A1 3737/4885BPTF 2443/4885SMN1; SMN2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.